Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider John Paolini Sells 18,413 Shares of Company Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) insider John Paolini sold 18,413 shares of the business’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $93.39, for a total value of $1,719,590.07. Following the sale, the insider owned 69,922 shares in the company, valued at approximately $6,530,015.58. This trade represents a 20.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Price Performance

Kiniksa Pharmaceuticals International stock opened at $93.29 on Wednesday. The business has a 50 day moving average of $79.67 and a 200-day moving average of $60.56. Kiniksa Pharmaceuticals International, plc has a 1 year low of $37.02 and a 1 year high of $98.48. The company has a market capitalization of $7.28 billion, a P/E ratio of 71.76 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The business had revenue of $285.97 million for the quarter, compared to the consensus estimate of $260.66 million. Equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.30 EPS for the current year.

Trending Headlines about Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Negative Sentiment: Across October 30 and November 2, CAO Michael Megna, COO Ross Moat, CFO Mark Ragosa and insider John Paolini reported sales totaling about 272,600 shares, worth approximately $25.4 million. The selling could weigh on sentiment or temper the stock’s recent momentum. However, each transaction was made under a pre-arranged Rule 10b5-1 plan, so it is not necessarily a response to new company developments. Megna SEC filing Moat SEC filing Paolini SEC filing Ragosa SEC filing

Institutional Trading of Kiniksa Pharmaceuticals International

Several institutional investors have recently added to or reduced their stakes in the stock. Rubric Capital Management LP raised its holdings in Kiniksa Pharmaceuticals International by 12.7% during the 1st quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock worth $180,562,000 after purchasing an additional 421,347 shares during the last quarter. Pictet Asset Management Holding SA lifted its position in shares of Kiniksa Pharmaceuticals International by 41.3% in the 3rd quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock worth $64,182,000 after purchasing an additional 251,578 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Kiniksa Pharmaceuticals International by 18.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock worth $39,086,000 after purchasing an additional 128,417 shares during the period. Spruce Street Capital LP lifted its position in shares of Kiniksa Pharmaceuticals International by 75.0% in the 1st quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock worth $36,645,000 after purchasing an additional 326,081 shares during the period. Finally, Bank of America Corp DE boosted its stake in shares of Kiniksa Pharmaceuticals International by 220.9% in the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after purchasing an additional 506,576 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Weiss Ratings downgraded shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. The Goldman Sachs Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the stock a “buy” rating in a research note on Wednesday, October 28th. Zacks Research downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Wells Fargo & Company raised their target price on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 28th. Finally, JPMorgan Chase & Co. lifted their target price on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has a consensus rating of “Moderate Buy” and an average price target of $100.57.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.